Inflammatory bowel disease and risk of urinary cancers: a systematic review and pooled analysis of population-based studies

被引:14
作者
Feng, Dechao [1 ,2 ]
Yang, Yubo [1 ]
Wang, Zhenghao [1 ]
Wei, Wuran [1 ]
Li, Li [2 ,3 ]
机构
[1] Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, Chengdu, Peoples R China
[2] Sichuan Univ, Minist Educ, Key Lab Birth Defects & Related Dis Women & Child, Chengdu, Peoples R China
[3] Sichuan Univ, West China Univ Hosp 2, Dept Pediat, 20,Sect 3, Chengdu 610041, Peoples R China
基金
中国国家自然科学基金;
关键词
Inflammatory bowel disease (IBD); bladder cancer; prostate cancer; renal cancer; COLORECTAL-CANCER; ULCERATIVE-COLITIS; AZATHIOPRINE; MALIGNANCIES; METAANALYSIS;
D O I
10.21037/tau-20-1358
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Background: The aim of this study is to elucidate the risk of urologic cancers in patients with Crohn's disease (CD) and ulcerative colitis (UC). Methods: Electronic databases including PubMed, the Cochrane Library, Embase and Web of Science, and manual retrieval were conducted from inception to June 2020. Two reviewers independently searched the above databases and selected the studies using prespecified standardized criteria. The Newcastle-Ottawa Scale was used to assess the risk of bias in the included studies, and this meta-analysis was completed by STATA version 14.2. Results: A total of 12 cohort studies and 4 case-control studies were included in this meta-analysis. Overall, patients with inflammatory bowel disease (IBD) were at significantly increased risk of renal cancer (RCa) [standardized incidence ratio (SIR): 1.53; 95% confidence interval (CI): 1.25-1.80; I-2=42.4%], but not at increased risk of prostate cancer (PCa), bladder cancer (BCa) and male genital cancer. In the subgroup analysis, CD patients had a significantly higher RCa risk (SIR: 1.95; 95% CI: 1.45-2.44; I-2=39.9%). Besides, CD patients seemed to be at borderline significantly increased risks of PCa (SIR: 1.07; 95% CI: 0.93-1.20; I(2=)15.1%) and BCa (SIR:1.19; 95% CI: 0.94-1.44; I-2=0%), and UC patients seemed to be at borderline significantly increased risks of RCa (SIR: 1.31; 95% CI: 0.94-1.67; I-2=48.0%) and PCa (SIR: 1.13; 95% CI: 0.93-1.33; I-2=73.5%). Notably, we observed that IBD patients in Eastern countries have significantly increased PCa risk (SIR: 2.66; 95% CI: 1.52-3.81; I-2=13.6%), especially for UC patients (SIR: 3.01; 95% CI: 1.75-4.27; I-2=0.0%). Conclusions: Our findings indicate that IBD patients with special reference to CD patients increase the risk of RCa. Besides, IBD patients in Asian countries have significantly increased risk of PCa, especially for UC patients. Further studies are warranted to elucidate the potential mechanism of RCa associated with IBD and the differences of the risk of urinary cancers between Eastern and Western countries.
引用
收藏
页码:1332 / +
页数:13
相关论文
共 40 条
  • [1] Has the risk of colorectal cancer in inflammatory bowel disease decreased?
    Andersen, Nynne Nyboe
    Jess, Tine
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (43) : 7561 - 7568
  • [2] [Anonymous], 2009, EVIDENCE BASED CF OX
  • [3] Risk of Cancer in Inflammatory Bowel Disease Treated With Azathioprine: A UK Population-Based Case-Control Study
    Armstrong, Richard G.
    West, Joe
    Card, Timothy R.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (07) : 1604 - 1609
  • [4] Gastroenterology 1 - Inflammatory bowel disease: cause and immunobiology
    Baumgart, Daniel C.
    Carding, Simon R.
    [J]. LANCET, 2007, 369 (9573) : 1627 - 1640
  • [5] Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
    Beaugerie, Laurent
    Brousse, Nicole
    Bouvier, Anne Marie
    Colombel, Jean Frederic
    Lemann, Marc
    Cosnes, Jacques
    Hebuterne, Xavier
    Cortot, Antoine
    Bouhnik, Yoram
    Gendre, Jean Pierre
    Simon, Tabassome
    Maynadie, Marc
    Hermine, Olivier
    Faivre, Jean
    Carrat, Fabrice
    [J]. LANCET, 2009, 374 (9701) : 1617 - 1625
  • [6] Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO
  • [7] 2-Z
  • [8] Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
    Bourrier, A.
    Carrat, F.
    Colombel, J. -F.
    Bouvier, A. -M.
    Abitbol, V.
    Marteau, P.
    Cosnes, J.
    Simon, T.
    Peyrin-Biroulet, L.
    Beaugerie, L.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (02) : 252 - 261
  • [9] Inflammatory Bowel Disease and the Risk of Prostate Cancer
    Burns, Jacob A.
    Weiner, Adam B.
    Catalona, William J.
    Li, Eric, V
    Schaeffer, Edward M.
    Hanauer, Stephen B.
    Strong, Scott
    Burns, James
    Hussain, Maha H. A.
    Kundu, Shilajit D.
    [J]. EUROPEAN UROLOGY, 2019, 75 (05) : 846 - 852
  • [10] EKBOM A, 1991, CANCER-AM CANCER SOC, V67, P2015, DOI 10.1002/1097-0142(19910401)67:7<2015::AID-CNCR2820670731>3.0.CO